Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 31, 2007

Axxam and Boehringer Ink Two Drug Research Agreements

  • Axxam signed two drug research collaboration agreements with Boehringer Ingelheim. The first collaboration agreement aims to identify and validate therapeutic targets with subsequent assay development, high-throughput screening (HTS), and lead optimizations.

    The second agreement covers the transfer of protein material and a corresponding specific functional assay for HTS to Boehringer Ingelheim.

    Axxam will receive fees as the collaboration progresses and milestone payments for successful exploitation of results through development stages.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »